Cartesian Therapeutics (RNAC) Stock Price, Quote, News & History

Q: What sector and industry does Cartesian Therapeutics (RNAC) operate in?

Cartesian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Cartesian Therapeutics Inc (RNAC) Stock Price, Quote, News & History

RNACNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$6.49

0.213.34%

At close: Feb 6, 4:00 PM EST

$6.69

0.203.08%

After Hours: Feb 6, 9:08 AM EST

Overview

News Earnings Options Analyst Ratings Insider Trades Short Interest Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$6.50

Close

$6.49

Volume / Avg.

122.82K / 166.24K

Day Range

$6.28 - $6.65

52 Wk Range

5.98 - 20.00

Market Cap

$173.96M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

20.57%

Days to Cover

13.62

Recent Cartesian Therapeutics Inc News

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.

Vandana Singh

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.

Vandana Singh

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-63.23M

Investing Cash Flow (TTM)

-5.32M

Financing Cash Flow (TTM)

-7.22M

Free Cash Flow (TTM)

-68.90M

Capital Expenditure (TTM)

-5.67M

Net Change in Cash (TTM)

-75.77M

Analyst Trends and Forecast

2

Nov 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$37.72M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

149.73

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-21.09%

Earnings Yield % (FWD)

-49.25%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.38

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$143.38M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$6.50

Close

$6.49

Volume / Avg.

122.82K / 166.24K

Day Range

$6.28 - $6.65

52 Wk Range

5.98 - 20.00

Market Cap

$173.96M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

20.57%

Days to Cover

13.62

About

Sector

Health Care

Industry

Biotechnology

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Cartesian Therapeutics (RNAC) stock?

A

You can purchase shares of Cartesian Therapeutics (NASDAQ:RNAC) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Cartesian Therapeutics (RNAC) competitors?

A

Other companies in Cartesian Therapeutics’s space includes: Molecular Partners AG (NASDAQ:MOLN), Kalaris Therapeutics Inc (NASDAQ:KLRS), Innate Pharma SA (NASDAQ:IPHA), Tharimmune Inc (NASDAQ:THAR) and Galectin Therapeutics Inc (NASDAQ:GALT).

Q

What is the forecast, or price target, for Cartesian Therapeutics (RNAC) stock?

A

Cartesian Therapeutics has a consensus price target of $39.50.

Q

What is the current price for Cartesian Therapeutics (RNAC)?

A

The stock price for Cartesian Therapeutics (NASDAQ: RNAC) is $6.69 last updated February 6, 2026 at 9:08 AM EST.

Q

Does Cartesian Therapeutics (RNAC) pay a dividend?

A

There are no upcoming dividends for Cartesian Therapeutics.

Q

When is Cartesian Therapeutics (NASDAQ:RNAC) reporting earnings?

A

Cartesian Therapeutics does not have any upcoming earnings scheduled.

Q

Is Cartesian Therapeutics (RNAC) going to split?

A

There is no upcoming split for Cartesian Therapeutics.

Q

What sector and industry does Cartesian Therapeutics (RNAC) operate in?

A

Cartesian Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Molecular Partners AG

NASDAQ:MOLN

$4.49

-4.47%

Kalaris Therapeutics Inc

Galectin Therapeutics Inc

Zentalis Pharmaceuticals Inc

NASDAQ:ZNTL

$2.29

-4.18%

ProQR Therapeutics NV

NASDAQ:PRQR

$1.43

-4.67%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$6.50

Close

$6.49

Volume / Avg.

122.82K / 166.24K

Day Range

$6.28 - $6.65

52 Wk Range

5.98 - 20.00

Market Cap

$173.96M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

20.57%

Days to Cover

13.62

Recent Cartesian Therapeutics Inc News

Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment

Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.

Vandana Singh

Cartesian Pauses Lupus And Multiple Myeloma Studies As It Shifts Development Focus

Cartesian Therapeutics shared initial data from Phase 2 trial of Descartes-08, showing potential for treating systemic lupus erythematosus.

Vandana Singh

Nvidia To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-63.23M

Investing Cash Flow (TTM)

-5.32M

Financing Cash Flow (TTM)

-7.22M

Free Cash Flow (TTM)

-68.90M

Capital Expenditure (TTM)

-5.67M

Net Change in Cash (TTM)

-75.77M

Analyst Trends and Forecast

2

Nov 25

1

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.2

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$37.72M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

149.73

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-21.09%

Earnings Yield % (FWD)

-49.25%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$1.38

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$143.38M

Debt to Equity

-

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$6.50

Close

$6.49

Volume / Avg.

122.82K / 166.24K

Day Range

$6.28 - $6.65

52 Wk Range

5.98 - 20.00

Market Cap

$173.96M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

39

Short Interest

20.57%

Days to Cover

13.62

About

Sector

Health Care

Industry

Biotechnology

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages ...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry